K1-3-HSA

K1-3-HSA is a recombinant fusion protein consisting of the first three kringle domains (K1-3) of human plasminogen fused to human serum albumin (HSA). It was developed as an anti-angiogenic agent, leveraging the known inhibitory effects of plasminogen fragments (such as angiostatin) on endothelial cell proliferation. The fusion with HSA is intended to extend the protein's circulatory half-life. In preclinical studies, K1-3-HSA was delivered via intramuscular plasmid electrotransfer, achieving a blood half-life of approximately 3.7 days. Although it demonstrated the ability to inhibit endothelial cell proliferation in vitro, it failed to show significant anti-tumor efficacy in mouse models, particularly when compared to the more potent K1-5 variant.

Other names

K1-3-human serum albumin fusion proteinK-1-3-human serum albumin fusion proteinK 1-3-human serum albumin fusion proteinplasminogen kringle 1-3-HSA